- Cecelia Health, a NYC-based technology-enabled diabetes and other chronic disease management company, closed a $13m Series B funding round
- The round co-led by Rittenhouse Ventures and Endo Investors, with participation from Boston Millennia Partners, SustainVC, G100 Capital, and others
- The company intends to use the funds to accelerate and further scale the adoption of its technology enabled coaching
- Cecelia Health will leverage the new funding to deliver a commercial Virtual Clinic that will offer CGM training
- Cecelia Health has emerged as a leader in using expert clinicians that leverage a technology-enabled digital health platform
- Later this month, Cecelia Health will serve as a contractor to The Jaeb Center for Health Research to conduct a study of a virtual diabetes
